Stocks
China Biologic Products Holdings Financial Statements (CBPO) |
||||||||||
| China Biologic Products Holdingssmart-lab.ru | % | 2016 | 2017 | 2018 | 2019 | 2020 | LTM ? | |||
|---|---|---|---|---|---|---|---|---|---|---|
| Report date | 23.02.2017 | 28.02.2018 | 06.03.2019 | 12.03.2020 | 31.12.2020 | 31.12.2020 | ||||
| Currency | USD | USD | USD | USD | USD | USD | ||||
| Financial report URL | ||||||||||
| Revenue, bln rub | ? | 341.2 | 370.4 | 466.9 | 503.7 | 524.4 | 524.4 | |||
| Operating Income, bln rub | 143.9 | 135.9 | 146.2 | 163.6 | 195.4 | 195.4 | ||||
| EBITDA, bln rub | ? | 142.9 | 145.6 | 169.7 | 193.7 | 215.5 | 215.5 | |||
| Net profit, bln rub | ? | 104.8 | 67.9 | 128.1 | 138.8 | 152.3 | 152.3 | |||
| OCF, bln rub | ? | 123.3 | 102.2 | 103.9 | 229.3 | 258.5 | 258.5 | |||
| CAPEX, bln rub | ? | 51.0 | 38.3 | 36.7 | 24.4 | 21.0 | 21.0 | |||
| FCF, bln rub | ? | 72.3 | 63.9 | 67.2 | 204.9 | 237.4 | 237.4 | |||
| Dividend payout, bln rub | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | ||||
| Ordinary share dividend yield, % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | ||||
| Dividend payout ratio, % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0 | ||||
| OPEX, bln rub | 73.2 | 109.0 | 173.9 | 165.4 | 149.1 | 149.1 | ||||
| Cost of production, bln rub | 124.0 | 125.5 | 146.8 | 174.7 | 179.9 | 179.9 | ||||
| R&D, bln rub | 7.02 | 6.50 | 9.52 | 11.7 | 8.58 | 8.58 | ||||
| Interest expenses, bln rub | 0.254 | 0.583 | 0.338 | 0.558 | 0.324 | 0.324 | ||||
| Assets, bln rub | 605.0 | 809.1 | 2 010 | 1 938 | 2 260 | 2 260 | ||||
| Net Assets, bln rub | ? | 521.1 | 664.3 | 1 845 | 1 775 | 2 082 | 2 082 | |||
| Debt, bln rub | 0.000 | 0.000 | 0.000 | 1.17 | 0.000 | 0.000 | ||||
| Cash, bln rub | 183.8 | 242.2 | 952.4 | 927.3 | 1 193 | 1 193 | ||||
| Net debt, bln rub | -183.8 | -242.2 | -952.4 | -926.1 | -1 193 | -1 193 | ||||
| Ordinary share price, rub | 107.5 | 78.8 | 75.9 | 116.4 | 118.1 | 117.9 | ||||
| Number of ordinary shares, mln | 26.8 | 27.4 | 35.4 | 38.9 | 38.7 | 38.7 | ||||
| Market cap, bln rub | 2 887 | 2 155 | 2 690 | 4 527 | 4 566 | 4 562 | ||||
| EV, bln rub | ? | 2 703 | 1 913 | 1 737 | 3 601 | 3 373 | 3 369 | |||
| Book value, bln rub | 498 | 639 | 1 446 | 1 394 | 1 682 | 1 682 | ||||
| EPS, rub | ? | 3.90 | 2.48 | 3.61 | 3.57 | 3.94 | 3.94 | |||
| FCF/share, rub | 2.69 | 2.34 | 1.90 | 5.27 | 6.14 | 6.14 | ||||
| BV/share, rub | 18.5 | 23.4 | 40.8 | 35.8 | 43.5 | 43.5 | ||||
| EBITDA margin, % | ? | 41.9% | 39.3% | 36.3% | 38.5% | 41.1% | 41.1% | |||
| Net margin, % | ? | 30.7% | 18.3% | 27.4% | 27.6% | 29.0% | 29.0% | |||
| FCF yield, % | ? | 2.50% | 2.96% | 2.50% | 4.53% | 5.20% | 5.21% | |||
| ROE, % | ? | 20.1% | 10.2% | 6.94% | 7.82% | 7.32% | 7.32% | |||
| ROA, % | ? | 17.3% | 8.40% | 6.37% | 7.16% | 6.74% | 6.74% | |||
| P/E | ? | 27.6 | 31.7 | 21.0 | 32.6 | 30.0 | 30.0 | |||
| P/FCF | 40.0 | 33.7 | 40.0 | 22.1 | 19.2 | 19.2 | ||||
| P/S | ? | 8.46 | 5.82 | 5.76 | 8.99 | 8.71 | 8.70 | |||
| P/BV | ? | 5.80 | 3.37 | 1.86 | 3.25 | 2.71 | 2.71 | |||
| EV/EBITDA | ? | 18.9 | 13.1 | 10.2 | 18.6 | 15.6 | 15.6 | |||
| Debt/EBITDA | -1.29 | -1.66 | -5.61 | -4.78 | -5.54 | -5.54 | ||||
| R&D/CAPEX, % | 13.8% | 17.0% | 25.9% | 48.0% | 40.8% | 40.8% | ||||
| CAPEX/Revenue, % | 15.0% | 10.3% | 7.86% | 4.85% | 4.01% | 4.01% | ||||
| China Biologic Products Holdings shareholders | ||||||||||
